RATIONALE:
Reduced upper airway muscle activity is fundamental to obstructive sleep apnea (OSA) pathogenesis. Prior research has demonstrated that hypoglossal nerve stimulation has the potential to reduce OSA severity without causing arousal from sleep. The objective of this study was to examine the safety and effectiveness of a novel hypoglossal nerve stimulation (HGNS™, Apnex Medical, Inc.) system as a potential treatment alternative for OSA.
METHODS:
Eighteen subjects with OSA but unable to tolerate continuous positive airway pressure (CPAP) underwent surgical implantation of the HGNS system in a feasibility study. The HGNS system is designed to stimulate the hypoglossal nerve during sleep, activating the genioglossus muscle synchronous with inspiration, which is sensed by changes in thoracic impedance. Apnea-hypopnea index (AHI) during laboratory polysomnography was used to measure OSA severity pre-implant and three months postimplant, which was two months after therapy initiation. Symptomatic response was assessed using Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ), Calgary Short Sleep Apnea Quality of Life Index (SAQLI), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Inventory (BDI). Paired ttests were used to assess changes from baseline. Mean nightly use (mean hours of use over all patient-nights) was calculated using at-home therapy utilization data stored by the HGNS system. Therapy adherence was defined as percent of subjects with mean nightly use ≥ 4 hours/night.
